If you search google news for ETC-216...
Good digging, but those articles have nothing that I'd call updated info on ETC-216 development. OTOH, those links both mention the Novartis HDL mimicking oral drug as promising.
The Novartis drug does sound promising, though I wonder how they handled the IP issue. Maybe it has nothing directly to do with Apo-A1 Milano, the IP Pfizer acquired with Esperion.
Urche
Market Data 
Markets 
AI
